Caitlin Lynch Selected Research

Cardiotoxicity

1/2022

Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caitlin Lynch Research Topics

Disease

4	Neoplasms (Cancer) 01/2022 - 05/2015
2	Obesity 01/2018 - 08/2014
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 08/2014
1	Cardiotoxicity 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Liver Diseases (Liver Disease) 01/2013
1	Breast Neoplasms (Breast Cancer) 12/2010

Drug/Important Bio-Agent (IBA)

2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2019
1	Orphan Nuclear ReceptorsIBA 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 01/2022
1	ERRalpha Estrogen-Related ReceptorIBA 01/2022
1	ProdrugsIBA 10/2019
1	DNA (Deoxyribonucleic Acid)IBA 10/2019
1	Nonesterified Fatty Acids (NEFA)IBA 01/2018
1	EnzymesIBA 01/2018
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 08/2014
1	Constitutive Androstane ReceptorIBA 08/2014
1	alcohol sulfotransferaseIBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 12/2010
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 12/2010
1	Omeprazole (Prilosec)FDA LinkGeneric 12/2010
1	MethylcholanthreneIBA 12/2010
1	Rosiglitazone (Avandia)FDA Link 12/2010
1	Imatinib Mesylate (Gleevec)FDA Link 12/2010

Therapy/Procedure

2	Therapeutics 01/2019 - 05/2015
1	Drug Therapy (Chemotherapy) 01/2022